Prostate cancer

breathcrumb

Prostate cancer

Prostate Cancer Biomarkers

Increasing levels

  • Increased core fucosylation and increase a2,3-sialic acid compared with BPH patients serum.
  • G0 significantly increased and G1 and α2-6 syalilation decreased in the IgG heavy chains of patients with prostate cancer.
  • Glycan Standard 13C Biantennary A1(3) (Sial α-2,3)
  • Glycan Standard 13C Tetraantennary A4-G1a
  • Bis α-2,6-sialylated biantennary glycopeptide from egg yolk
  • Bis α-2,3-sialylated, galactosylated biantennary glycopeptide

Prostate Cancer Biomarkers

Decreasing levels

  • Decreased sialylation of PSA subforms in seminal plasma.
  • Poor prognosis is associated with decreased levels of fucosylated glycans and increased levels of sialylated compounds.
  • Bis α-2,3-sialylated, galactosylated biantennary glycopeptide

References:
[19] R. Saldova, et al., Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia, Glycobiology 21 (2011) 195–205.

[38] Kazuno S et al. “Glycosylation status of serum immunoglobulin G in patients with prostate diseases.”Cancer Med. 2016.

[20] A. Sarrats, et al., Glycan characterization of PSA 2-DE subforms from serum and seminal plasma, OMICS: A J. of Integr. Biol. 14 (2010) 465–474.

[21] A. Sarrats, et al., Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis, Prostate 70 (2010) 1–9.

[22] Hua, S., et al., (2011) Comprehensive native glycan profiling with isomer separation and quantitation for the discovery of cancer biomarkers. Analyst 136, 3663–3671.